MEMPHIS, Tenn., Nov. 19, 2015 /PRNewswire/ -- Hapten Sciences, Inc., a privately held biotechnology company, announced today that it has filed an Investigational New Drug (IND) application and is now planning to initiate dosing of healthy volunteers in a first-in-human Phase 1...